Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.46 |
| ▸ | NOS1 | P29475 | 4/20 | 0.45 |
| ▸ | NOS3 | P29474 | 2/20 | 0.45 |
| ▸ | NOS2 | P35228 | 2/20 | 0.45 |
| ▸ | DDAH1 | O94760 | 4/20 | 0.43 |
| ▸ | GSR | P00390 | 1/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.42 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | RRM1 | P23921 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3508097 | 1.00 | OTC (0.50) | OTCDPP7NOD1NOS1NOS3 | |
| Hydrochloric Acid SCHEMBL30271216 | 0.98 | OTC (0.49) | OTCDPP7NOD1NOS1NOS3 | |
| SCHEMBL8730134 | 0.93 | NOD1 (0.52) | OTCDPP7NOD1NOS1NOS3 | |
| SCHEMBL21111056 | 0.92 | DPP7 (0.58) | OTCDPP7NOD1NOS1NOS3 | |
| SCHEMBL12028765 | 0.90 | OTC (0.50) | OTCDPP7NOD1NOS1NOS3 | |
| SCHEMBL21089975 | 0.90 | OTC (0.50) | OTCDPP7NOD1NOS1NOS3 | |
| SCHEMBL1344672 | 0.90 | SLC1A2 (0.42) | OTCDPP7NOD1NOS1NOS3 | |
| Arginine SCHEMBL2100608 | 0.89 | OTC (0.49) | OTCDPP7NOD1NOS1NOS3 | |
| SCHEMBL29551297 | 0.89 | DPP7 (0.54) | OTCDPP7NOD1NOS1NOS3 | |
| SCHEMBL30302208 | 0.85 | DPP7 (0.46) | OTCDPP7NOD1NOS1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| WO-2024231899-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-11-14 | — | — | WO | claimed |
| CN-118406439-B | Chemical mechanical polishing composition and application thereof in tungsten chemical mechanical polishing | 万华化学集团电子材料有限公司 | 2024-10-18 | — | — | CN | claimed |
| CN-118406439-A | Chemical mechanical polishing composition and application thereof in tungsten chemical mechanical polishing | 万华化学集团电子材料有限公司 | 2024-07-30 | — | — | CN | claimed |
| US-20260083844-A1 | DOWNREGULATING INOS TO INCREASE CAR-T KILLING | H LEE MOFFITT CANCER CT & RES (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024231899-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-11-14 | — | — | WO | disclosed |
| CN-118406439-B | Chemical mechanical polishing composition and application thereof in tungsten chemical mechanical polishing | 万华化学集团电子材料有限公司 | 2024-10-18 | — | — | CN | disclosed |
| CN-118406439-A | Chemical mechanical polishing composition and application thereof in tungsten chemical mechanical polishing | 万华化学集团电子材料有限公司 | 2024-07-30 | — | — | CN | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| WO-2018204764-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION (US) | 2018-11-08 | — | — | WO | disclosed |
| US-20150309021-A1 | Advanced Drug Development and Manufacturing | LOS ALAMOS NATIONAL SECURITY, LLC | 2015-10-29 | — | — | US | disclosed |
| US-20100183645-A1 | ACTIVE OR PASSIVE IMMUNIZATION AGAINST PROAPOPTOTIC NEUROTROPHINS FOR THE TREATMENT AND/OR PREVENTION OF NEURODEGENERATIVE DISEASES | INSTITUT PASTEUR (FR) | 2010-07-22 | — | — | US | disclosed |
| US-20100087370-A1 | MODULATION OF NITRIC OXIDE SIGNALING TO NORMALIZE TUMOR VASCULATURE | THE GENERAL HOSPITAL CORPORATION (US) | 2010-04-08 | — | — | US | disclosed |
| EP-2084519-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | Los Alamos National Security, LLC (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| US-20060275290-A1 | Active or passive immunization against proapoptotic neurotrophins for the treatment and/or prevention of neurodegenerative diseases | INSTITUT PASTEUR (FR) | 2006-12-07 | — | — | US | disclosed |
| US-7045307-B2 | Method for measuring no synthase activity | GRUENENTHAL GMBH (DE) | 2006-05-16 | — | — | US | disclosed |
| US-20040002129-A1 | Method for measuring no synthase activity | GRUENENTHAL GMBH. | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083844-A1 | DOWNREGULATING INOS TO INCREASE CAR-T KILLING | NOS2, NOS1, NOS3 | OTC 1371/4885DPP7 4741/4885NOD1 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.